semaglutide alzheimer's disease clinical trial disease: use linked to lower risk Clinical trials of new drugs

Study reveals potential eye risk for Semaglutide (Ozempic) users Study has found a troubling link between the use of semaglutide (marketed as Ozempic or Wegovy) and an increased risk of developing a potentially blinding eye condition A recent study led by researchers at Mass Eye and Ear has found a troubling link between the use of semaglutide (marketed as Ozempic or Wegovy) and an increased risk of developing a potentially blinding eye condition known as NAION (non-arteritic anterior ischemic optic neuropathy)

Typically, eligibility requires a BMI of 30 or higher, or a BMI of 27 or higher alongside a weight-related health condition (such as high blood pressure or type 2 diabetes)

Find out more here

This review aims to provide an overview of oxidative stress and inflammation in endometriosis, and comprehensively summarize the effects and potential mechanisms of various dietary patterns and nutrients in endometriosis (Figure 1)